These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 1389893)
1. In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats. Tsukamoto E Ann Nucl Med; 1992 Aug; 6(3):177-84. PubMed ID: 1389893 [TBL] [Abstract][Full Text] [Related]
2. Tc-99m labeled tissue-type plasminogen activator: preparation, stability and preliminary imaging of thrombus-bearing rats. Itoh K; Tsukamoto E; Nishibe T; Sakurama S; Ieko M; Tanabe T; Furudate M Ann Nucl Med; 1991 Jul; 5(2):59-64. PubMed ID: 1777351 [TBL] [Abstract][Full Text] [Related]
3. Technetium-99m-labeled recombinant tissue plasminogen activator for the imaging of emboli in vivo. Takahashi A; Itoh K; Tsukamoto E; Furudate M; Kamiyama H; Abe H Neurol Med Chir (Tokyo); 1993 Jul; 33(7):415-9. PubMed ID: 7692316 [TBL] [Abstract][Full Text] [Related]
4. Aging of acute deep vein thrombosis measured by radiolabeled 99mTc-rt-PA. Brighton T; Janssen J; Butler SP J Nucl Med; 2007 Jun; 48(6):873-8. PubMed ID: 17504873 [TBL] [Abstract][Full Text] [Related]
5. In vivo kinetics of 99mTc labeled recombinant tissue plasminogen activator in rabbits. Itoh K; Ieko M; Hiraguchi E; Kitayama H; Tsukamoto E Ann Nucl Med; 1994 Aug; 8(3):193-9. PubMed ID: 7811562 [TBL] [Abstract][Full Text] [Related]
6. Rapid localization of indium-111-labeled inhibited recombinant tissue plasminogen activator in a rabbit thrombosis model. Butler SP; Kader KL; Owen J; Wang TS; Fawwaz RA; Alderson PO J Nucl Med; 1991 Mar; 32(3):461-7. PubMed ID: 1900886 [TBL] [Abstract][Full Text] [Related]
7. Characterization of indium-111 labeled recombinant tissue plasminogen activator for the imaging of thrombi. Hnatowich DJ; Virzi F; Doherty PW; Wilson J; Rosa J; Ansell JE Eur J Nucl Med; 1987; 13(9):467-73. PubMed ID: 3126072 [TBL] [Abstract][Full Text] [Related]
8. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line. Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244 [TBL] [Abstract][Full Text] [Related]
9. Clot uptake of labeled active and inhibited tissue plasminogen activator. Lavie E; Bitton M; Shalev J; Weininger J; Abrashkin S; Varga E; Lubin E; Azoury R Biochim Biophys Acta; 1989 Apr; 991(1):62-7. PubMed ID: 2496763 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of LVAD Thrombus using a High-Avidity Fibrin-Specific Cui G; Akers WJ; Scott MJ; Nassif M; Allen JS; Schmieder AH; Paranandi KS; Itoh A; Beyder DD; Achilefu S; Ewald GA; Lanza GM Theranostics; 2018; 8(4):1168-1179. PubMed ID: 29464007 [TBL] [Abstract][Full Text] [Related]
11. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
12. Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro. Devcic-Kuhar B; Pfaffenberger S; Gherardini L; Mayer C; Gröschl M; Kaun C; Benes E; Tschachler E; Huber K; Maurer G; Wojta J; Gottsauner-Wolf M Thromb Haemost; 2004 Nov; 92(5):980-5. PubMed ID: 15543323 [TBL] [Abstract][Full Text] [Related]
13. 99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo. Edwards D; Lewis J; Battle M; Lear R; Farrar G; Jon Barnett D; Godden V; Oliveira A; Coombes C; Ahlström H Nucl Med Commun; 2007 Jan; 28(1):55-62. PubMed ID: 17159550 [TBL] [Abstract][Full Text] [Related]
14. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Francis CW; Blinc A; Lee S; Cox C Ultrasound Med Biol; 1995; 21(3):419-24. PubMed ID: 7645133 [TBL] [Abstract][Full Text] [Related]
15. Fibrin affinity and clearance of t-PA deletion and substitution analogues. Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048 [TBL] [Abstract][Full Text] [Related]
16. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis. Chen LY; Nichols WW; Saldeen TG; Mehta JL J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429 [TBL] [Abstract][Full Text] [Related]
19. (99m)Tc-NC100668, a new tracer for imaging venous thromboemboli: pre-clinical biodistribution and incorporation into plasma clots in vivo and in vitro. Edwards D; Lewis J; Battle M; Lear R; Farrar G; Barnett DJ; Godden V; Oliveira A; Coombes C; Ahlström H Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1258-65. PubMed ID: 16804686 [TBL] [Abstract][Full Text] [Related]
20. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates. Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]